secwatch.observer — SEC 8-K summary
======================================

Issuer:     PepGen Inc. (PEPG)
CIK:        0001835597
Form:       8-K
Filed at:   2023-06-13T23:59:59+00:00
Accession:  0000950170-23-027696
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

PepGen withdraws PGN-EDODM1 Phase 1 timeline guidance pending FDA clinical hold
-------------------------------------------------------------------------------

- Withdrawing prior guidance to initiate a Phase 1 study of PGN-EDODM1 in DM1 in H1 2023.
- Awaiting official clinical hold letter from FDA; pausing additional regulatory filings to address the hold.
- CEO committed to working with FDA to lift the hold and start study as quickly as feasible.
- Company remains focused on advancing Phase 2 CONNECT1-EDO51 study in Duchenne muscular dystrophy, cleared by Health Canada in May 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1835597/000095017023027696/0000950170-23-027696-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1835597/000095017023027696/pepg-20230613.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-027696

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer